Navigation Links
Soligenix Reports Year-End 2010 Financial Results and Highlights Recent Accomplishments
Date:3/29/2011

PRINCETON, N.J., March 29, 2011 /PRNewswire/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today its financial results for the year ended December 31, 2010.

Soligenix's revenues for the year ended December 31, 2010 were $1,947,628 as compared to $2,816,037 for the prior year, representing a decrease of $868,409, or 31%.  During 2009, Soligenix received a $1 million milestone payment from Sigma-Tau Pharmaceuticals, Inc., the Company's collaborative partner on the orBec® Phase 3 clinical trial in the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), which did not reoccur in 2010.

Soligenix's net loss for the year ended December 31, 2010 was $7,386,579 as compared to a net loss of $6,034,453 for the prior year, representing an increase of $1,352,126, or 22%. This increase is primarily attributed to increased spending of $1,160,934 in research and development related to conducting the Phase 3 orBec® study.

Research and development expenses for the year ended December 31, 2010 were $5,684,309, compared to $4,523,375 for the prior year. For the year ended December 31, 21010, there was also a decrease in general and administrative expenses of $349,458, which reflects decreases in compensation associated with severance, benefits and board fees in 2010.

"We expect 2011 to be a pivotal year for us," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "We are looking forward to completing our confirmatory Phase 3 clinical trial of orBec® in the treatment of acute GI GVHD.  We remain committed to our goal of having orBec® become the first FDA-approved therapy to treat this life-threatening condition which is an area of unmet medical need associated high morbidity rates."

Soligenix's Recent H
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
2. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
3. Soligenix to Present at 8th Annual BIO Investor Forum
4. Soligenix to Present at 12th Annual BIO CEO & Investor Conference
5. Soligenix Reports Third Quarter 2009 Financial Results
6. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
7. Soligenix Announces Completion of Patient Enrollment in Phase 2 Acute GVHD Prevention Clinical Trial
8. Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments
9. Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate
10. Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors
11. Soligenix Reports Second Quarter 2010 Financial Results and Reviews Accomplishments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4ld5nw/mature_biotech ) ... Outlook 2015: New Therapy Ventures Pave the Way for ... All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen ... given a positive return and hence increased the interest ... select therapy/niche indication where the high treatment cost justifies ...
(Date:3/5/2015)... e2b teknologies , a premier ... Northeast Ohio, today announced a leading independent multi-specialty physician ... upgrade to the latest version of Sage 100 ... of its kind in the region, the organization has ... so efficiency and data accessibility are paramount to their ...
(Date:3/5/2015)... Southlake, Texas (PRWEB) March 05, 2015 ... treatment of acute and chronic orthopedic conditions such ... runner’s knee, tennis elbow, and joint pain due ... also be administered during orthopedic surgeries to promote ... patented scientific advances in nearly pain-free bone marrow ...
(Date:3/4/2015)... -- In an article published and posted online today, ... review the clinical aspects of diseases caused by 5 ... article, "Clinical Management of Potential Bioterrorism-Related Conditions," was published ... New England Journal of Medicine . ... Tom Inglesby—review the clinical management of conditions resulting from ...
Breaking Biology Technology:Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5Latest Clinical Information On Bioterrorism Threats 2
... , May 17 Sigma-Aldrich Corporation (Nasdaq: SIAL ) will ... 20th at 1:15 PM CDT ( 2:15 PM EDT ) ... over the Internet available at http://investor.sigmaaldrich.com/ .  Users can click the "Webcast" ... , , ...
... May 17 TriReme Medical, Inc. (TMI) announced today that ... for its GliderXtreme™ PTA balloon catheter. GliderXtreme™ is now approved for ... balloon diameters from 2.0 – 5.0mm and in balloon lengths up ... , ...
... 17 ViroPharma Incorporated (Nasdaq: VPHM ) today ... Cinryze™ (C1 Esterase Inhibitor [Human]) in preventing and treating attacks ... Health,s online clinical trial registry, www.clinicaltrials.gov . The data ... data from the CHANGE 2 acute treatment study will be ...
Cached Biology Technology:Sigma-Aldrich Corporation to Present at the Baird's 2010 Growth Stock Conference on Thursday, May 20, 2010 2TriReme Medical, Inc. Receives FDA 510(k) Clearance for a Broad Matrix of GliderXtreme(TM) PTA Balloon Catheter Sizes 2ViroPharma Announces Availability of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Final Open-Label Data 2ViroPharma Announces Availability of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Final Open-Label Data 3ViroPharma Announces Availability of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Final Open-Label Data 4ViroPharma Announces Availability of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Final Open-Label Data 5ViroPharma Announces Availability of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Final Open-Label Data 6ViroPharma Announces Availability of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Final Open-Label Data 7
(Date:3/5/2015)... 5, 2015 In Brazil , ... already using these solutions and 42 percent planning to invest ... approximately 25 percent of the companies will be investing in ... majority of companies in the region are currently opting for ... model will command significant attention in the coming years. This ...
(Date:3/4/2015)... Mar. 04, 2015 Research and Markets ... of the "Global Biometrics Market Forecast and ... The market for biometric authentication systems is ... 14% till 2020 The driving forces ... security needs, government projects and constant development in ...
(Date:3/3/2015)... , March 3, 2015 ... provider of advanced cryogenic logistics solutions for ... immunotherapies, stem cells, cell lines, clinical research ... medicine, today announced the expansion of its ... Centers, ("Fred Hutch") Clinical Research Division ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... the University of Leicester has proposed an immense (1.5km) exhibition ... a vivid perspective of how quickly human activity is changing ... at a rate of a few centimetres every thousand years. ... vertically down into the sea bed to extract a sample ...
... 1 The U.S. Department of Homeland,Security ... collecting additional,fingerprints from international visitors arriving at ... change is part of the,department,s upgrade from ... facilitate legitimate travel by more accurately and,efficiently ...
... Mouse and rat brain atlases have long ... traditional brain atlases offer an incomplete map ... Reference Atlas: A Digital Color Brain Atlas ... Edition; January 2008; $195.00; 376 Pages; Paperback; ...
Cached Biology News:DHS Begins Collecting 10 Fingerprints From International Visitors at George Bush Houston Intercontinental Airport 2Book is the first high-resolution digital mouse brain atlas designed for Web applications 2
Mouse polyclonal antibody to PRDM2 - PR domain containing 2, with ZNF domain...
Hepatocyte Differentiation Environment...
Mouse monoclonal [M2II-12] to MRP2 ( Abpromise for all tested applications). entrezGeneID: 1244 SwissProtID: Q92887...
...
Biology Products: